B
54.26
0.45 (0.84%)
| Previous Close | 53.81 |
| Open | 54.71 |
| Volume | 1,491,489 |
| Avg. Volume (3M) | 2,379,617 |
| Market Cap | 10,372,803,584 |
| Price / Sales | 42.85 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Operating Margin (TTM) | -89.00% |
| Diluted EPS (TTM) | -3.56 |
| Quarterly Revenue Growth (YOY) | -44.80% |
| Current Ratio (MRQ) | 4.57 |
| Operating Cash Flow (TTM) | -500.42 M |
| Levered Free Cash Flow (TTM) | -261.20 M |
| Return on Assets (TTM) | -48.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | BridgeBio Pharma, Inc. | Bullish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 3.0 |
| Insider Activity | -2.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 4.97% |
| % Held by Institutions | 98.14% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 110.00 (Cantor Fitzgerald, 102.73%) | Buy |
| Median | 90.00 (65.87%) | |
| Low | 70.00 (JP Morgan, 29.01%) | Buy |
| Average | 88.44 (62.99%) | |
| Total | 9 Buy | |
| Avg. Price @ Call | 60.50 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 03 Nov 2025 | 90.00 (65.87%) | Buy | 61.98 |
| 29 Oct 2025 | 90.00 (65.87%) | Buy | 66.62 | |
| Goldman Sachs | 31 Oct 2025 | 100.00 (84.30%) | Buy | 62.64 |
| Cantor Fitzgerald | 30 Oct 2025 | 110.00 (102.73%) | Buy | 63.37 |
| Piper Sandler | 30 Oct 2025 | 98.00 (80.61%) | Buy | 63.37 |
| Raymond James | 30 Oct 2025 | 71.00 (30.85%) | Buy | 63.37 |
| 21 Oct 2025 | 59.00 (8.74%) | Buy | 54.36 | |
| TD Cowen | 30 Oct 2025 | 95.00 (75.08%) | Buy | 63.37 |
| Truist Securities | 30 Oct 2025 | 80.00 (47.44%) | Buy | 63.37 |
| UBS | 12 Sep 2025 | 82.00 (51.12%) | Buy | 51.21 |
| JP Morgan | 03 Sep 2025 | 70.00 (29.01%) | Buy | 51.84 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MCCORMICK FRANK | - | 65.09 | -200,000 | -13,318,979 |
| Aggregate Net Quantity | -200,000 | |||
| Aggregate Net Value ($) | -13,318,979 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 65.09 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MCCORMICK FRANK | Director | 29 Oct 2025 | Automatic sell (-) | 198,359 | 66.62 | 13,214,677 |
| MCCORMICK FRANK | Director | 27 Oct 2025 | Automatic sell (-) | 1,641 | 63.56 | 104,302 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |